![Alon Lazarus](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Alon Lazarus
Direttore/Membro del Consiglio presso WEREWOLF THERAPEUTICS, INC.
Patrimonio netto: - $ in data 31/05/2024
Profilo
Dr. Alon Lazarus is an Independent Director at Werewolf Therapeutics, Inc. and a Biotech Investment Manager at Arkin Bio Ventures.
He is on the Board of Directors at Werewolf Therapeutics, Inc., Auron Therapeutics, Inc., Bluejay Therapeutics, Inc., Entact Bio, Inc., Lutris Pharma Ltd., Paros Bio, Inc. and Photys Therapeutics, Inc. Dr. Lazarus was previously employed as an Independent Director by Keros Therapeutics, Inc., a Manager-Biotech Investment by Arkin Holdings, a Head-Business Development by Yissum Holdings Ltd., and an Analyst by Integra Holdings Ltd.
He also served on the board at Pantheon Biosciences Ltd., Oncorus, Inc., Entact Bio Ltd.
and Quiet Therapeutics Ltd.
He received his undergraduate degree from The Hebrew University of Jerusalem, an MBA from The Hebrew University of Jerusalem and a doctorate degree from The Hebrew University Hadassah Medical School.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
21/06/2023 | 0 ( -.--% ) | - $ | 31/05/2024 |
Posizioni attive di Alon Lazarus
Società | Posizione | Inizio |
---|---|---|
WEREWOLF THERAPEUTICS, INC. | Direttore/Membro del Consiglio | 01/08/2019 |
Paros Bio, Inc.
![]() Paros Bio, Inc. BiotechnologyHealth Technology Paros Bio, Inc. is a private company that specializes in gene therapy for neurodegenerative diseases. The company is based in Boston, MA. The company is focused on developing a gene replacement approach to treat autosomal dominant Alzheimer's disease (ADAD). Specifically, they are working on a gene therapy that targets mutations in the presenilin 1 gene (PSEN1), which is the underlying genetic cause of ADAD. | Direttore/Membro del Consiglio | - |
Bluejay Therapeutics, Inc.
![]() Bluejay Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Bluejay Therapeutics, Inc. is a clinical stage private biopharmaceutical company that is committed to developing effective treatments and cures for viral and liver diseases. The company is based in San Mateo, CA, and was founded by Keting Chu, who has been the CEO since incorporation. The company's first target indication is chronic hepatitis b, which is a worldwide prevalent disease with an urgent unmet medical need. Bluejay is advancing two innovative approaches with the potential for a high rate of functional cure: fully human igg1 anti-hbs monoclonal antibodies and first-in-class hbsag oral small molecule inhibitors. The company believes that by reducing hepatitis b surface antigen and restoring adaptive immunity, a functional cure could be achieved for patients. | Direttore/Membro del Consiglio | - |
Photys Therapeutics, Inc.
![]() Photys Therapeutics, Inc. Medical SpecialtiesHealth Technology Photys Therapeutics, Inc. is a company based in Cambridge, MA that was founded by Longwood Fund and Dr. Amit Choudhary of Brigham and Women's Hospital and the Broad Institute of MIT and Harvard. The company is advancing phosphorylation inducing chimeric small molecules (PHICs), a proprietary new class of bifunctional medicines that direct and repair protein phosphorylation to treat a range of diseases including cancer, immune, metabolic, and rare diseases. PHICs enhance the pairing of specific kinases with disease target proteins, inducing precise phosphorylation at native and/or non-native sites, modulating key functions including activation, stabilization, trafficking, localization, phospho-antigen presentation, inactivation, degradation, and interactions of proteins. The company's approach unlocks diverse classes of targets, developing a new class of medicines for precise control of protein function. The company was founded by Amit Choudhary, David Steinberg, Edward Holson, Lizzie Ngo. David Steinberg has been the CEO since incorporation. | Direttore/Membro del Consiglio | - |
Auron Therapeutics, Inc.
![]() Auron Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Auron Therapeutics, Inc. operates as a biotechnology company. It aims to cure cancer by radically changing the paradigm of cancer therapeutics from cell killing to transformation of malignant cells into more normal functioning cells. The company was founded by Kate Yen, Matt Vander Heiden, Ross Levine, and Eytan Stein and is headquartered in Wellesley, MA. | Direttore/Membro del Consiglio | - |
Arkin Bio Ventures
![]() Arkin Bio Ventures Investment ManagersFinance Arkin Bio Ventures (Arkin Bio) is a venture capital arm of Arkin Holdings founded in 2016. The firm is headquartered in Tel Aviv, Israel. | Investitore di Private Equity | 01/08/2013 |
Lutris Pharma Ltd.
![]() Lutris Pharma Ltd. Pharmaceuticals: MajorHealth Technology Lutris Pharma Ltd. is working on the improvement of the anti-cancer therapy effectiveness and the quality of life for patients that are treated with Epidermal Growth Factor Receptor Inhibitors. The company was founded on December 14, 2015 and is headquartered in Tel Aviv, Israel. | Direttore/Membro del Consiglio | - |
Entact Bio, Inc.
![]() Entact Bio, Inc. BiotechnologyHealth Technology Entact Bio, Inc. is a company that focuses on creating new medicines by enhancing protein function. The company is based in Watertown, MA. The company is a team of scientists, entrepreneurs, drug creators, and problem solvers who work together to bring new medicines to patients who currently have few options. The CEO of the company is Victoria M. Richon. The founder of the company grew up in chaos and instability in an undisclosed capital city and has always been passionate and motivated to help enhance and provide medical solutions. | Direttore/Membro del Consiglio | - |
Precedenti posizioni note di Alon Lazarus
Società | Posizione | Fine |
---|---|---|
Locki Therapeutics Ltd.
![]() Locki Therapeutics Ltd. BiotechnologyHealth Technology Locki Therapeutics Ltd. is a British preclinical stage biotechnology company founded in 2019. The company is based in London, UK. Locki Therapeutics is developing a new class of drugs that enhance the function of beneficial proteins. The company has designed its proprietary encompass™ platform to create enhancement-targeting chimeric (entac™) medicines. These entacs harness the ability of dubs to regulate proteins, expanding the universe of treatable diseases. | Direttore/Membro del Consiglio | 11/10/2023 |
░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░░ ░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░░ ░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░ ░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░ ░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Formazione di Alon Lazarus
The Hebrew University Hadassah Medical School | Doctorate Degree |
The Hebrew University of Jerusalem | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 3 |
---|---|
KEROS THERAPEUTICS, INC. | Health Technology |
ONCORUS, INC. | Health Technology |
WEREWOLF THERAPEUTICS, INC. | Health Technology |
Aziende private | 13 |
---|---|
Quiet Therapeutics Ltd.
![]() Quiet Therapeutics Ltd. Medical SpecialtiesHealth Technology Quiet Therapeutics Ltd. develops a proprietary nanoparticle-based delivery system for the targeted delivery of chemotherapy and anti-inflammatory drugs. It developed a class of cancer therapeutics called GAGomers, enables the flexibility of delivering a medicine that can kill the cancer cells and block the production of proteins that promote the cancer. The company was founded by Dan Peer and Rimona Margalit in 2009 and is headquartered in Ness Ziona, Israel. | Health Technology |
Lutris Pharma Ltd.
![]() Lutris Pharma Ltd. Pharmaceuticals: MajorHealth Technology Lutris Pharma Ltd. is working on the improvement of the anti-cancer therapy effectiveness and the quality of life for patients that are treated with Epidermal Growth Factor Receptor Inhibitors. The company was founded on December 14, 2015 and is headquartered in Tel Aviv, Israel. | Health Technology |
Arkin Bio Ventures
![]() Arkin Bio Ventures Investment ManagersFinance Arkin Bio Ventures (Arkin Bio) is a venture capital arm of Arkin Holdings founded in 2016. The firm is headquartered in Tel Aviv, Israel. | Finance |
Arkin Holdings
![]() Arkin Holdings Real Estate Investment TrustsFinance Arkin Holdings engages in the provision of healthcare investment services which specializes in pharmaceutical and biotechnology, medical devices, dermatology, and hedge fund. The company was founded by Mori Arkin in 2009 and is headquartered in Herzliya, Israel. | Finance |
Auron Therapeutics, Inc.
![]() Auron Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Auron Therapeutics, Inc. operates as a biotechnology company. It aims to cure cancer by radically changing the paradigm of cancer therapeutics from cell killing to transformation of malignant cells into more normal functioning cells. The company was founded by Kate Yen, Matt Vander Heiden, Ross Levine, and Eytan Stein and is headquartered in Wellesley, MA. | Commercial Services |
Integra Holdings Ltd.
![]() Integra Holdings Ltd. MiscellaneousMiscellaneous Integra Holdings Ltd. operates as a holding company. It invests in the pharmaceutical industry. The company was founded in 2012 and is headquartered in Jerusalem, Israel. | Miscellaneous |
Photys Therapeutics, Inc.
![]() Photys Therapeutics, Inc. Medical SpecialtiesHealth Technology Photys Therapeutics, Inc. is a company based in Cambridge, MA that was founded by Longwood Fund and Dr. Amit Choudhary of Brigham and Women's Hospital and the Broad Institute of MIT and Harvard. The company is advancing phosphorylation inducing chimeric small molecules (PHICs), a proprietary new class of bifunctional medicines that direct and repair protein phosphorylation to treat a range of diseases including cancer, immune, metabolic, and rare diseases. PHICs enhance the pairing of specific kinases with disease target proteins, inducing precise phosphorylation at native and/or non-native sites, modulating key functions including activation, stabilization, trafficking, localization, phospho-antigen presentation, inactivation, degradation, and interactions of proteins. The company's approach unlocks diverse classes of targets, developing a new class of medicines for precise control of protein function. The company was founded by Amit Choudhary, David Steinberg, Edward Holson, Lizzie Ngo. David Steinberg has been the CEO since incorporation. | Health Technology |
Locki Therapeutics Ltd.
![]() Locki Therapeutics Ltd. BiotechnologyHealth Technology Locki Therapeutics Ltd. is a British preclinical stage biotechnology company founded in 2019. The company is based in London, UK. Locki Therapeutics is developing a new class of drugs that enhance the function of beneficial proteins. The company has designed its proprietary encompass™ platform to create enhancement-targeting chimeric (entac™) medicines. These entacs harness the ability of dubs to regulate proteins, expanding the universe of treatable diseases. | Health Technology |
Bluejay Therapeutics, Inc.
![]() Bluejay Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Bluejay Therapeutics, Inc. is a clinical stage private biopharmaceutical company that is committed to developing effective treatments and cures for viral and liver diseases. The company is based in San Mateo, CA, and was founded by Keting Chu, who has been the CEO since incorporation. The company's first target indication is chronic hepatitis b, which is a worldwide prevalent disease with an urgent unmet medical need. Bluejay is advancing two innovative approaches with the potential for a high rate of functional cure: fully human igg1 anti-hbs monoclonal antibodies and first-in-class hbsag oral small molecule inhibitors. The company believes that by reducing hepatitis b surface antigen and restoring adaptive immunity, a functional cure could be achieved for patients. | Commercial Services |
Yissum Holdings Ltd. | |
Paros Bio, Inc.
![]() Paros Bio, Inc. BiotechnologyHealth Technology Paros Bio, Inc. is a private company that specializes in gene therapy for neurodegenerative diseases. The company is based in Boston, MA. The company is focused on developing a gene replacement approach to treat autosomal dominant Alzheimer's disease (ADAD). Specifically, they are working on a gene therapy that targets mutations in the presenilin 1 gene (PSEN1), which is the underlying genetic cause of ADAD. | Health Technology |
Pantheon Biosciences Ltd.
![]() Pantheon Biosciences Ltd. Miscellaneous Commercial ServicesCommercial Services Pantheon Biosciences Ltd. is an Israeli company that develops molecular therapies and tools. The company is based in Yavne, Israel and was founded in 2017. | Commercial Services |
Entact Bio, Inc.
![]() Entact Bio, Inc. BiotechnologyHealth Technology Entact Bio, Inc. is a company that focuses on creating new medicines by enhancing protein function. The company is based in Watertown, MA. The company is a team of scientists, entrepreneurs, drug creators, and problem solvers who work together to bring new medicines to patients who currently have few options. The CEO of the company is Victoria M. Richon. The founder of the company grew up in chaos and instability in an undisclosed capital city and has always been passionate and motivated to help enhance and provide medical solutions. | Health Technology |
- Borsa valori
- Insiders
- Alon Lazarus